Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BLRX vs TLPH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TLPH Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 6–2 Matrix Metrics)

TLPH Overall Winner 6-Pillar Tally: BLRX 2 – 2 TLPH (2 Tie) Matrix Metrics: BLRX 2 – 6 TLPH

As of Nov 16, 2026, Talphera, Inc. (TLPH) is the stronger overall head-to-head candidate over BioLineRX Ltd (BLRX) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale). BLRX carries a Unified Composite Score of 37.1/100 (SELL) at $1.18 (93.5x Forward P/E, -874.3% operating margin), whereas TLPH carries 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin).

  • Defensive Composite Rating Caution: Although TLPH compares more favorably head-to-head, both BLRX (37.1/100 SELL) and TLPH (37.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: BLRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 12.2); meanwhile TLPH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BLRX vs TLPH
BLRX NASDAQ
BioLineRX Ltd
Pharmaceutical Preparations
$1.18
-9.23% 1D
Market Cap $6.9M
TTM Revenue $1.4M
Forward P/E 93.5x
Beta / 30D Vol 0.45β · 68% Vol
Unified Composite Score
37.1 / 100 SELL
Tech 25.0 Fund 49.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.2%), weak momentum, RSI 12
RSI-14: 12.2 · SMA20: $1.81 · SMA50: $2.14
TLPH NASDAQ Head-to-Head Winner
Talphera, Inc. Common Stock
Pharmaceutical Preparations
$0.86
-4.98% 1D
Market Cap $53.7M
TTM Revenue $1,000
Forward P/E 1.0x
Beta / 30D Vol 1.11β · 58% Vol
Unified Composite Score
37.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.8%), weak momentum, RSI 26
RSI-14: 26.1 · SMA20: $1.04 · SMA50: $1.10

6-Pillar Scorecard Institutional Category Breakdown (BLRX 2 – 2 TLPH)

Columns: Metric · BLRX · TLPH
1. Valuation Multiples TLPH
Forward P/E 93.5x 1.0x
Trailing P/E 93.5x 1.0x
PEG Ratio 0.20x N/M
EV / Revenue 5.0x N/M
2. Growth & Scale TLPH
Revenue Growth (YoY) -3.3% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1.4M $1,000
Market Cap $6.9M $53.7M
3. Profitability & Quality BLRX
Gross Margin 80.0% N/A
Operating Margin -874.3% -1474700.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -55.3% -143.4%
4. Balance Sheet & Cash Flow BLRX
Cash Generation (TTM) -$12M EBITDA -$15M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $3.00 Book/Sh · -55.3% ROE $0.28 Book/Sh · -143.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 226.3% (50th %ile) 118.4% (100th %ile)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BLRX (2) vs TLPH (6)
Institutional Metric BLRX TLPH Criterion Row Edge
Market Capitalization
Scale
$6.9M $53.7M Larger Scale TLPH
Trailing P/E Ratio
Valuation
93.5x 1.0x Lower Multiple TLPH
Forward P/E Ratio
Valuation
93.5x 1.0x Lower Multiple TLPH
Revenue Growth (YoY)
Growth
-3.3% +0.0% Higher Growth TLPH
Operating Margin (TTM)
Profitability
-874.3% -1474700.0% Higher Margin BLRX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-55.3% -143.4% Higher ROE BLRX
52-Week Range Position
Momentum
1% ($1–$4) 20% ($1–$2) Stronger Trend TLPH
Beta / 30D Volatility
Risk Regime
0.45β · 68% Vol 1.11β · 58% Vol Lower Realized Risk TLPH
Unified Institutional Score
Composite Signal
37.1 / 100 (SELL) 37.1 / 100 (SELL) Higher Composite Tie
Trailing 12M Revenue (USD)
Operating Scale
$1.4M $1,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
80.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.20x PEG · 5.0x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$12M EBITDA ($3.00 Book/Sh · -55.3% ROE) -$15M EBITDA ($0.28 Book/Sh · -143.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TLPH +21.0 pp
BLRX: -41.29% · TLPH: -20.29%
3M Horizon TLPH +29.75 pp
BLRX: -58.6% · TLPH: -28.85%
6M Horizon TLPH +65.76 pp
BLRX: -57.78% · TLPH: +7.98%
1Y Horizon TLPH +47.98 pp
BLRX: -65.99% · TLPH: -18.01%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BLRX vs TLPH. Trailing 12-month operating profitability (BLRX -874.3% vs TLPH -1474700.0%) and valuation multiples (BLRX 93.5x vs TLPH 1.0x Forward P/E) are benchmarked directly in Pillar 4 below.

BLRX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.4M
Gross Margin80.0%
Op. Margin-874.3%
ROE / Fwd P/E-55.3% · 93.5x
TLPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1,000
Gross MarginN/A
Op. Margin-1474700.0%
ROE / Fwd P/E-143.4% · 1.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BLRX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 226.3%
IV Percentile 50th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BLRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TLPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 118.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TLPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BLRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $6.9M market capitalization and -874.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TLPH Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $53.7M market capitalization and -1474700.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BLRX vs TLPH Key Questions & Quantitative Answers

As of Nov 16, 2026, Talphera, Inc. (TLPH) is the stronger overall head-to-head candidate over BioLineRX Ltd (BLRX) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale). BLRX carries a Unified Composite Score of 37.1/100 (SELL) at $1.18 (93.5x Forward P/E, -874.3% operating margin), whereas TLPH carries 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin). Defensive Composite Rating Caution: Although TLPH compares more favorably head-to-head, both BLRX (37.1/100 SELL) and TLPH (37.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: BLRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 12.2); meanwhile TLPH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TLPH leads the Growth & Scale pillar: BLRX posts -3.3% YoY revenue growth and +0.0% YoY earnings growth on $1.4M TTM revenue (80.0% gross margin, -874.3% operating margin), compared with TLPH at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1,000 TTM revenue (N/A gross margin, -1474700.0% operating margin). On trailing 12-month operating scale, BLRX generates $1.4M in USD-normalized revenue versus $1,000 for TLPH. In operating R&D and SG&A reinvestment, BLRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for TLPH.

TLPH screens cheaper on headline valuation multiples. BLRX trades at 93.5x Forward P/E, 93.5x Trailing P/E, 0.20x PEG, and 5.0x EV/Revenue (unreported EBITDA margin), whereas TLPH trades at 1.0x Forward P/E, 1.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BLRX (-55.3% ROE) versus TLPH (-143.4% ROE) capital efficiency.

In options market volatility and institutional positioning, BLRX carries 226.3% implied volatility (50th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.45β · 68% Vol realized risk). By comparison, TLPH carries 118.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.11β · 58% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.